IONS Ionis Pharmaceuticals Inc.

42.95
+0.78  (+2%)
Previous Close 42.17
Open 42.26
Price To Book 17.9
Market Cap 5391100321
Shares 125,520,380
Volume 1,001,765
Short Ratio 9.14
Av. Daily Volume 1,295,472

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2b initiated.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Phase 1/2 data presented April 24, 2018 at AAN.
IONIS-HTT Rx
Huntington's Disease
Phase 2b completion of enrollment announced February 7, 2018. Data due 2H 2018.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. PDUFA date under priority review extended to October 6, 2018.
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
PDUFA August 30, 2017. Advisory Committee Meeting May 10, 2018 voted 10-8 in favor.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.